Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BLTE Stock Forecast 2026-2027
$153.68
Current Price
$5.77B
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to BLTE Price Targets
+30.1%
To High Target of $200.00
+24.3%
To Median Target of $191.00
-8.9%
To Low Target of $140.00
BLTE Price Momentum
-6.3%
1 Week Change
+7.8%
1 Month Change
+179.9%
1 Year Change
-3.9%
Year-to-Date Change
-9.7%
From 52W High of $170.25
+213.6%
From 52W Low of $49.00
📊 TOP ANALYST CALLS
Did BLTE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Belite Bio is one of their latest high-conviction picks.
Latest BLTE Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, BLTE has a bullish consensus with a median price target of $191.00 (ranging from $140.00 to $200.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $153.68, the median forecast implies a 24.3% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BLTE Analyst Ratings
7
Buy
0
Hold
0
Sell
BLTE Price Target Range
Low
$140.00
Average
$191.00
High
$200.00
Current: $153.68
Latest BLTE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BLTE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 6, 2026 | Morgan Stanley | Judah Frommer | Overweight | Initiates | $191.00 |
| Dec 2, 2025 | Mizuho | Graig Suvannavejh | Outperform | Upgrade | $194.00 |
| Dec 1, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $185.00 |
| Nov 24, 2025 | Cantor Fitzgerald | Steve Seedhouse | Overweight | Assumes | $154.00 |
| Nov 20, 2025 | Mizuho | Graig Suvannavejh | Neutral | Initiates | $105.00 |
| Oct 31, 2025 | Benchmark | Bruce D. Jackson | Buy | Maintains | $132.00 |
| Sep 15, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $98.00 |
| Jul 3, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $100.00 |
| May 15, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $100.00 |
| May 15, 2025 | Cantor Fitzgerald | Jennifer Kim | Overweight | Reiterates | $N/A |
| Mar 26, 2025 | Benchmark | Bruce Jackson | Buy | Reiterates | $80.00 |
| Mar 18, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $100.00 |
| Mar 18, 2025 | Cantor Fitzgerald | Jennifer Kim | Overweight | Reiterates | $N/A |
| Jan 21, 2025 | Benchmark | Bruce Jackson | Buy | Maintains | $79.00 |
| Nov 15, 2024 | Maxim Group | Jason McCarthy | Buy | Maintains | $110.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $100.00 |
| Sep 12, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $60.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $60.00 |
| Aug 13, 2024 | Benchmark | Bruce Jackson | Buy | Reiterates | $57.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Jennifer Kim | Overweight | Reiterates | $N/A |
Belite Bio, Inc. (BLTE) Competitors
The following stocks are similar to Belite Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Belite Bio, Inc. (BLTE) Financial Data
Belite Bio, Inc. has a market capitalization of $5.77B with a P/E ratio of -130.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -32.3%.
Valuation Metrics
Market Cap
$5.77B
Enterprise Value
$5.13B
P/E Ratio
-130.2x
PEG Ratio
-1.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+5.1%
Current Ratio
34.4x
Debt/Equity
0.2x
ROE
-32.3%
ROA
-21.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Belite Bio, Inc. (BLTE) Business Model
About Belite Bio, Inc.
What They Do
Develops therapeutics for metabolic diseases and eye conditions.
Business Model
Belite Bio generates revenue through the discovery, development, and commercialization of biopharmaceuticals that address unmet medical needs. The company focuses on innovative treatments for conditions like NASH and Stargardt Disease, leveraging research in mitochondrial dysfunctions and genetic disorders to create therapies with potential market demand.
Additional Information
Belite Bio is positioned as a significant player in the biotechnology industry, engaging in pioneering research that could lead to transformative therapies. Its commitment to addressing root causes of complex health issues aims to improve patient outcomes and advance medical science.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
25
CEO
Dr. Yu-Hsin Lin M.B.A., Ph.D.
Country
United States
IPO Year
2022
Website
www.belitebio.comBelite Bio, Inc. (BLTE) Latest News & Analysis
Latest News
Quick Summary
Belite Bio's experimental drug for a rare genetic eye disease achieved its primary endpoint in a late-stage study, indicating progress in its development.
Why It Matters
Positive results from Belite Bio's late-stage study could boost the company’s stock value, attract partnerships, and signal potential market approval, impacting investor sentiment and future profitability.
Source: Reuters
Market Sentiment:
Positive
Why Belite Bio Stock Soared on Monday
1 month ago
Quick Summary
A biotech company's Stargardt disease drug showed positive results in a late-stage clinical trial, indicating potential for treating this vision-loss condition.
Why It Matters
Positive trial results for the Stargardt disease drug enhance the biotech's growth potential, signaling strong market demand and possible revenue increases, impacting stock performance favorably.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Belite Bio Inc. (NASDAQ: BLTE) announced successful topline results from the Phase 3 DRAGON trial of Tinlarebant for treating Stargardt disease type 1 (STGD1).
Why It Matters
Successful Phase 3 results for Tinlarebant in STGD1 could boost Belite Bio's stock, enhance market confidence, and attract potential partnerships or acquisitions in the biotech sector.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Belite Bio, Inc (BLTE) reported positive topline results from the Phase III DRAGON trial of Tinlarebant for treating Stargardt disease.
Why It Matters
Positive Phase III trial results for Tinlarebant in Stargardt Disease enhance Belite Bio's growth potential, likely boosting investor confidence and stock value due to increased market prospects.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Belite Bio (NASDAQ: BLTE) announced successful topline results from its Phase 3 "DRAGON" trial for Tinlarebant, the first pivotal trial for treating Stargardt disease type 1, with no current approved treatment.
Why It Matters
Successful Phase 3 trial results for Tinlarebant position Belite Bio as a leader in treating Stargardt disease, potentially opening new revenue streams and driving stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
1 month ago
Quick Summary
Belite Bio, Inc. (NASDAQ: BLTE) has launched an underwritten public offering of American Depositary Shares, with plans for underwriters to have a 30-day option for additional ADSs.
Why It Matters
Belite Bio's public offering can impact share dilution and liquidity, affecting stock price and investor sentiment. Market conditions will influence the offering's success and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BLTE Stock
What is Belite Bio, Inc.'s (BLTE) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Belite Bio, Inc. (BLTE) has a median price target of $191.00. The highest price target is $200.00 and the lowest is $140.00.
Is BLTE stock a good investment in 2026?
According to current analyst ratings, BLTE has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $153.68. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BLTE stock?
Wall Street analysts predict BLTE stock could reach $191.00 in the next 12 months. This represents a 24.3% increase from the current price of $153.68. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Belite Bio, Inc.'s business model?
Belite Bio generates revenue through the discovery, development, and commercialization of biopharmaceuticals that address unmet medical needs. The company focuses on innovative treatments for conditions like NASH and Stargardt Disease, leveraging research in mitochondrial dysfunctions and genetic disorders to create therapies with potential market demand.
What is the highest forecasted price for BLTE Belite Bio, Inc.?
The highest price target for BLTE is $200.00 from at , which represents a 30.1% increase from the current price of $153.68.
What is the lowest forecasted price for BLTE Belite Bio, Inc.?
The lowest price target for BLTE is $140.00 from at , which represents a -8.9% decrease from the current price of $153.68.
What is the overall BLTE consensus from analysts for Belite Bio, Inc.?
The overall analyst consensus for BLTE is bullish. Out of 10 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $191.00.
How accurate are BLTE stock price projections?
Stock price projections, including those for Belite Bio, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 6:55 AM UTC